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Metabolic switches in various immune cell subsets
enforce phenotype and function. In the present
study, we demonstrate that the active form of vitamin
D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), induces
human monocyte-derived tolerogenic dendritic cells
(DC) by metabolic reprogramming. Microarray anal-
ysis demonstrated that 1,25(OH)2D3 upregulated
several genes directly related to glucose meta-
bolism, tricarboxylic acid cycle (TCA), and oxidative
phosphorylation (OXPHOS). Although OXPHOS was
promoted by 1,25(OH)2D3, hypoxia did not change
the tolerogenic function of 1,25(OH)2D3-treated
DCs. Instead, glucose availability and glycolysis,
controlled by the PI3K/Akt/mTOR pathway, dictate
the induction and maintenance of the 1,25(OH)2D3-
conditioned tolerogenic DC phenotype and fun-
ction. This metabolic reprogramming is unique for
1,25(OH)2D3, because the tolerogenic DC phenotype
induced by other immunemodulators did not depend
on similar metabolic changes. We put forward that
these metabolic insights in tolerogenic DC biology
can be used to advance DC-based immunother-
apies, influencing DC longevity and their resistance
to environmental metabolic stress.INTRODUCTION
Besides the well-established function of the active vitamin D
metabolite as central regulator of mineral and bone homeosta-Cesis, 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) has been rediscov-
ered as a major modulator of the immune system, playing a po-
tential physiological role in the regulation of innate and adaptive
immune responses. Although affecting the immune system at
different levels, the main target of vitamin D in a mixed immune
population is the dendritic cell (DC). In these cells, 1,25(OH)2D3
can generate in vitro a stable maturation-resistant tolerogenic
phenotype, with low expression of HLA-DR, low expression of
costimulatory molecules (e.g., CD80, CD86), and increased
interleukin 10 (IL-10)/IL-12p70 ratios that aremaintained even af-
ter removal of the compound (van Halteren et al., 2002). Impor-
tantly, introduction of an antigen in parallel with 1,25(OH)2D3
can induce antigen-specific tolerogenic DCs (tolDCs) (Unger
et al., 2009) with the capacity to induce infectious tolerance,
changing the behavior of other proinflammatory mature DCs
through the induction of antigen-specific regulatory T cells
(Tregs), and causing the perpetuation of the tolerogenic res-
ponse (Kleijwegt et al., 2011). In addition, 1,25(OH)2D3-condi-
tioned fully differentiated DCs (1,25D3-DCs) lose their ability to
activate autoreactive T cells, stimulating instead the generation
of Tregs (Ferreira et al., 2014; Unger et al., 2009; van Halteren
et al., 2002, 2004). Reintroduction of such 1,25D3-DCs in vivo
leads to immune modulation (Ferreira et al., 2014), which repre-
sents a reliable strategy for the promotion or restoration of
antigen-specific tolerance through vaccination strategies, for
example, in type 1 diabetes patients. Although these immuno-
modulatory effects of 1,25(OH)2D3 on DC phenotype and func-
tion are well delineated, the intracellular and molecular mecha-
nisms leading to these tolerogenic properties remain largely
unknown.
Recently, metabolic regulation has emerged as an essen-
tial mechanism to control the function, growth, proliferation,
and survival of various immune cell subsets, an area of research
referred to as ‘‘immunometabolism’’ (Williams et al., 2013). Thus,ll Reports 10, 711–725, February 10, 2015 ª2015 The Authors 711
the crosstalk between different immune signals and the meta-
bolic status of T cells and macrophages, in particular, direct
key immune cell-fate decisions (Michalek et al., 2011; Vats
et al., 2006; Zeng et al., 2013). Moreover, metabolic changes
occur within minutes in murine DCs upon toll-like receptor
(TLR)-inducedmaturation and commit DCs to switch from oxida-
tive phosphorylation (OXPHOS) to glycolysis. TANK-binding ki-
nase 1 (TKB1), IkB kinase-ε (IKKε), and Akt signaling were shown
to be essential for the TLR-induced transition to aerobic glycol-
ysis by promoting the association of the glycolytic enzyme
hexokinase-2 (HK2) with mitochondria. This metabolic pathway
seems crucial for sustaining cell survival and function (Everts
et al., 2012, 2014; Krawczyk et al., 2010).
Building on our previous findings obtained by proteomic
analysis suggesting that 1,25(OH)2D3 has a major impact on
metabolic proteins in fully differentiated DCs (Ferreira et al.,
2012), we have now studied the early intracellular pathways acti-
vated by 1,25(OH)2D3 in these cells. This was done by a combi-
nation of transcriptome analysis and functional studies of the
identified pathways, with a major focus on metabolic changes.
The data obtained indicate that 1,25(OH)2D3 initiates an early
transcriptional reprogramming of metabolic pathways in not
yet fully differentiated human DCs (differentiating monocytes,
dMo) that favors OXPHOS, which is accompanied by increased
aerobic glycolysis. Furthermore, 1,25D3-DCs, but not tolDCs
generated by other biological and pharmacological agents,
rely on glucose availability and usage, as well as on the PI3K/
Akt/mTOR pathway, for the induction and maintenance of
their tolerogenic phenotype. The present findings show that
1,25(OH)2D3 affects the phenotype and behavior of DCs through
its impact on cellular metabolic pathways, driving both OXPHOS
and glycolysis in a way that is unique to this compound.
RESULTS
Tolerogenic DCs Generated by 1,25(OH)2D3 Present an
Early and Transcriptionally Mediated Metabolic
Reprogramming
In order to elucidate the molecular mechanisms underlying the
tolerogenic properties of 1,25D3-DCs, we performed microarray
analysis of human dMo at 4 and 24 hr after addition of differen-
tiation media (e.g., IL-4 and granulocyte macrophage colony-
stimulating factor [GM-CSF]) and 1,25(OH)2D3 (10
8 M) (Fig-
ure S1). These early time points were chosen based on the
observation that a single dose of 1,25(OH)2D3 to dMo at the start
of the in vitro DC culture was sufficient to generate the tolero-
genic profile, because we observed a similar decrease in
CD80/HLA-DR and an increase in CD14 surface expression,
when compared to DCs exposed to two administrations of
1,25(OH)2D3 (Sze´les et al., 2009; Figure S2). Four hours of treat-
ment with 1,25(OH)2D3 induced the differential expression of 100
genes, compared to controls (1.3-fold change; adjusted p < 0.01)
(Figure S3A, left panel). Among these are known 1,25(OH)2D3-
regulated genes, such as CYP24A1, CCL22, CD14, CD200,
and CA2 (Figure S3A, right panel), confirming the early respon-
siveness of this cell type to 1,25(OH)2D3 (Figure S3B). Comparing
the transcriptomes of 1,25(OH)2D3-conditioned and vehicle-
treated samples after 24 hr of in vitro culture revealed the differ-712 Cell Reports 10, 711–725, February 10, 2015 ª2015 The Authorsential expression of 1,558 genes. Only 68 of these were modified
by the hormone at both time points (Figure S3A, left panel).
Classification of the genes affected after 24 hr of 1,25(OH)2D3
treatment by Gene Ontology (GO) revealed that four out of
the top nine preferentially affected biological processes corre-
sponded to metabolism-related pathways, namely, tricarboxylic
acid cycle (TCA), OXPHOS, respiratory electron transport chain
(ETC), and mitochondrial electron transport, NADH to ubiqui-
none (all p < 0.05 compared to vehicle-treated dMo) (Table
S1). Similarly, grouping this set of genes according to their func-
tion in different biological pathways using Reactome, seven out
of the top 12 affected pathways were related to metabolic pro-
cesses (Table S2).
To identify candidate pathways preferentially affected by
1,25(OH)2D3 treatment in human dMo, we subjected the same
set of genes to ingenuity pathway analysis (IPA). This revealed
that 1,25(OH)2D3 treatment induced several highly ranked ca-
nonical pathways related to oxidative metabolism and glycolytic
control, namely, OXPHOS, mitochondrial dysfunction, the TCA
cycle, and PI3K signaling (Figure S3C; Table S3). The majority
of the genes related to the TCA cycle, and OXPHOS were upre-
gulated after 1,25(OH)2D3 treatment compared to control condi-
tion (Figure S4). Similarly, key metabolic genes involved in
glucose uptake and glycolytic commitment/control were upre-
gulated by the hormone, whereas mRNA expression of inhibitory
molecules, such as pyruvate dehydrogenase kinase isozyme 4
(PDK4), were downregulated (Figure S4). Taken, together these
results indicate that 1,25(OH)2D3 induces an early metabolic re-
programming in human dMo, which is characterized by the tran-
scriptional upregulation of several genes directly related to the
TCA cycle, OXPHOS, and glucose metabolism.
Tolerogenic DCs Induced by 1,25(OH)2D3 Have an
Increased Oxidative Metabolism
The main transcripts related to glucose metabolism, the TCA
cycle, and OXPHOS identified by the microarray analysis are
shown in Figures 1A and 2A. qRT-PCR was used to validate
the observed changes in some of these key genes, confirming
an upregulated mRNA expression 24 hr after addition of
1,25(OH)2D3 of glucose receptor 3 (GLUT3), the glucose receptor
of white blood cells; hexokinase 3 (HK3), the enzyme responsible
for committing glucose to the glycolytic pathway; 6-phospho-
fructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), which
regulates phosphofructokinase and functions as regulatory en-
zyme of glycolysis, besides being a putative direct target of
1,25(OH)2D3 in THP-1 cells (Heikkinen et al., 2011); pyruvate
dehydrogenase alpha 1 (PDHA1), one of the subunits of the pyru-
vate dehydrogenase complex and a central link between glycol-
ysis and the TCA cycle; ATP synthase subunit alpha 1 (ATP5A1),
which catalyzes ATP synthesis during OXPHOS; and lactate de-
hydrogenase A (LDHA), which produces lactate from pyruvate
during glycolysis (Figure 1B).
Interestingly, AMPK, a master regulator of ATP production
through fatty acid (FA) oxidation, was upregulated 24 hr after
addition of 1,25(OH)2D3 to the human dMo cultures (Figure 1C).
The total protein levels of ACC, a direct AMPK target, were also
induced in human dMo conditioned by 1,25(OH)2D3 as early as
48 hr after addition of the hormone, whereas its phosphorylation
levels were slightly upregulated in the same samples, as com-
pared to controls (Figure 1D).
Because OXPHOS is often linked to the induction of a tolero-
genic phenotype of different immune cell subsets (Michalek
et al., 2011; Vats et al., 2006), we performed functional assays
to further investigate whether human 1,25D3-DCs showed fea-
tures pointing to an induced OXPHOS metabolism. Treatment
with the hormone increased the intracellular ATP content and
ROS production, as compared to controls, throughout the com-
plete culture period (Figure 1E). Furthermore, the mitochondrial
membrane potential and total mitochondrial mass were in-
creased by 1,25(OH)2D3 in human dMo (Figure 1F). Finally, hu-
man 1,25D3-DCs showed a clear trend for higher basal oxygen
consumption rate (OCR) (Figure 1G) and a significantly increased
glucose oxidation (Figure 1H), as compared to controls. Interest-
ingly, FA and glutamine (Q) oxidation rates were not significantly
changed in human 1,25D3-DCs (Figure 1H). Together, these data
support the view that human tolDCs obtained in vitro in the pres-
ence of 1,25(OH)2D3 have an increased OXPHOS profile with
glucose as main oxidative fuel, a process that is maintained
throughout the differentiation/maturation culture period.
1,25(OH)2D3-Modulated Tolerogenic DCs Perform
Increased Glycolysis in the Presence of Oxygen
The microarray data described above suggested that human
1,25D3-DCs not only have increased oxidation, but also perform
increased glycolysis. This is clear from the induced expression of
both PFKFB4 and LDHA (Figure 1B), as well as several other en-
zymes directly involved in this pathway in human dMo condi-
tioned by 1,25(OH)2D3 (Figure 2A). We further evaluated whether
this increased glycolytic transcriptional profile was paralleled by
an altered functional profile. The basal extracellular acidification
rate (ECAR), which indicates pH changes that may occur due to
lactate production, was increased in human 1,25D3-DCs as
compared to vehicle-treated control DCs (Ctr-DCs) (Figure 2B).
In line with this, 1,25D3-DCs secreted increasing levels of lactate,
as evidenced by an accumulation of the media lactate content
throughout the complete in vitro culture period. This was
accompanied by increased glucose uptake rates and a gradual
decrease in the media glucose content, as compared to controls
(Figure 2C). Finally, human 1,25D3-DCs clearly present an induc-
tion in their glycolytic rate, as compared to controls (Figure 2D).
Taken together, these data show that human tolDCs obtained
in vitro in the presence of 1,25(OH)2D3 use glucose as metabolic
fuel in both OXPHOS and aerobic glycolysis.
Glucose Availability Plays an Essential Role in Inducing
and Maintaining the Tolerogenic Phenotype and
Function of 1,25(OH)2D3-Treated DCs
Next, we investigated the impact of glucose availability in
inducing and maintaining the 1,25D3-DC phenotype in vitro. As
expected, human 1,25D3-DCs obtained at 10 mM glucose pre-
sented a typical tolerogenic cell-surface phenotype, with lower
expression levels of CD80, CD86, and HLA-DR and increased
IL-10/IL-12p70 ratios as compared to Ctr-DCs (Figure 3A).
When subjecting human dMo to a glucose-limiting condition,
i.e., 1mM, the 1,25D3-DC phenotype was completely prevented,
as evidenced by unaltered CD86 and HLA-DR expression andCeincreased CD80 levels as compared to controls, without impact-
ing cell survival (Figures 3A and S5A). In line with this, lower IL-
10/IL-12p70 ratios were detected during glucose deprivation
(versus similar culture conditions at 10 mM glucose availability,
see Figure 3A). The prevention of the tolerogenic phenotype
induced by 1,25(OH)2D3 in human DCs was confirmed after eval-
uation of T cell proliferation and interferon g (IFN-g) secretion into
the culture supernatants, because 1,25D3-DCs obtained in the
presence of 1 mM glucose partially restored their ability to pro-
mote T cell proliferation. This was especially clear for CD4+
T cells and was followed by a full impairment in IFN-g secretion
into the coculture supernatants, as compared to their respective
controls (Figure 3A). Interestingly, adjusting glucose levels to
10 mM every day during the in vitro culture period neither
improved the tolerogenic surface phenotype of 1,25D3-DCs (Fig-
ure S5B), nor altered the rate of glucose consumption and lactate
production (Figures S5C–S5F). These experiments allowed us to
conclude that sufficiently available glucose in culture media,
especially in the beginning of the differentiation period, plays
an essential role in the induction and maintenance of the tolero-
genic phenotype of human 1,25D3-DCs.
Next, we attempted to generate in vitro human 1,25D3-DCs in
hypoxic conditions (0.2% available oxygen) and thus under
limiting OXPHOS rates. These conditions partially impaired the
tolerogenic effects of 1,25(OH)2D3 on the surface expression of
CD86 and HLA-DR of human DCs. These alterations did not
change the ability of 1,25D3-DCs to hamper T cell function
in vitro, even though IFN-g secretion was affected, indicating
that oxygen availability did not play an essential role in inducing
and maintaining the tolerogenic function of human 1,25D3-DCs.
Limiting the availability of oxygen did however impair 1,25D3-DC
survival (Figures 3B and S5G).
Glycolysis, but Not Glucose and FA Oxidation, Is
Essential for the Induction and Maintenance of the
Tolerogenic Phenotype of 1,25(OH)2D3-Modulated DCs
Because glucose uptake, oxidation, and especially glycolysis
was clearly induced in human 1,25D3-DCs, we tried to obtain
1,25D3-DCs in the presence of 2-deoxy-D-glucose (2-DG), a
glucose analog that is phosphorylated by HK to 2-DG-phos-
phate, which cannot be further metabolized. Accumulation of
2-DG-phosphate inhibits glycolysis causing ATP depletion. Pre-
vious studies have used low doses of 2-DG to address the
influence of glycolysis in directing the cell fate of CD4+ Th17
cells versus Foxp3+ Tregs (Michalek et al., 2011; Shi et al.,
2011). Addition of 5 mM 2-DG to human iDC conditioned with
1,25(OH)2D3 decreased the accumulation of lactate in the media
(as compared to 1,25D3-DCs obtained in 10 mM glucose media,
Figure 4A), prevented the downregulation of HLA-DR, CD80 and
CD86, in addition to decreasing the IL-10/IL-12 ratios (as
compared to 1,25D3-DCs) (Figure 4B). The inhibition of the tol-
erogenic phenotype of the human 1,25D3-DCs was confirmed
after evaluation of T cell proliferation, because 1,25D3-DCs ob-
tained in the presence of 5 mM 2-DG partially restored their abil-
ity to promote T cell function, especially CD4+ T cell proliferation
(Figure 4B).
We next exposed human 1,25D3-DCs to dichloroacetate
(DCA) (a PDK inhibitor, which pushes glucose-derived pyruvatell Reports 10, 711–725, February 10, 2015 ª2015 The Authors 713
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Figure 2. 1,25(OH)2D3-Modulated DCs Have Increased Glycolytic Metabolism
(A) Heatmap generated frommicroarray data reflecting differentially expressed genes corresponding to proteins included in the glycolytic branch of themetabolic
pathway.
(B) Basal ECAR of Ctr- or 1,25D3-DCs measured using Seahorse technology (n = 3; *p < 0.05); media lactate content of Ctr- (white bars) or 1,25D3-DCs (black
bars), measured daily during the complete differentiation and maturation period from monocytes (n = 3–7; **p < 0.01, ***p < 0.001, ****p < 0.0001).
(C) Glucose uptake of Ctr- (white bars) or 1,25D3-DCs (black bars) (n = 4; *p < 0.05 as compared to controls); media glucose content of Ctr- (white bars) or 1,25D3-
DCs (black bars), measured daily during the complete differentiation and maturation period from monocytes (n = 3–7; **p < 0.01, ***p < 0.001, ****p < 0.0001).
(D) Glycolytic flux of Ctr- (white bars) or 1,25D3-DCs (black bars) (n = 3–4; p < 0.01). Values depicted in the bar graphs represent average levels ± SEM from either
metabolite in the supernatants of Ctr- (white bars) or 1,25D3-DC (black bars) cultures.into the mitochondria for further metabolism and thus induces
metabolic switch from glycolysis to mitochondrial respiration;
Figure 4A) to investigate whether the fate of pyruvate is important
in the induction and maintenance of a tolerogenic profile in
1,25D3-DCs. Also here, in spite of a reversal in the expressionFigure 1. 1,25(OH)2D3-Modulated DCs Have an Upregulated Oxidative
(A) Heatmaps generated from the microarray data reflecting differentially expres
metabolic pathway.
(B) Confirmation of differential mRNA expression of GLUT3, HK3, PFKFB4, PDHA
bars) (n = 5–12; *p < 0.05, **p < 0.01).
(C) Confirmation of differential expression of the relative mRNA levels of PRKAA1
bars) (n = 6; *p < 0.05).
(D) Total protein lysates of Ctr- and 1,25D3-dMo samples prepared at days 1
phosphorylated and total ACC (normalized to b-actin) were determined by west
induction/inhibition of the analyzed proteins in Ctr- versus 1,25D3-dMo by weste
(E) Intracellular ATP content (left) and ROS production (right) in Ctr- or 1,25D3-dM
change in the production of either metabolite in 1,25(OH)2D3-modulated cells, as
(F) Mitochondrial membrane potential measured after JC-1 staining of ethanol-
determined after staining with Mitotracker green and FACS analysis of Ctr- or 1,
(G) Basal OCR of Ctr- or 1,25D3-DCs measured by Seahorse technology (n = 3).
(H) Glucose (1 and 10 mM available glucose), FA, and Q oxidation rates of Ctr- (
controls).
In (A)–(H), values depicted in the bar graphs represent average ± SEM from the m
Ceof CD86 on the DC cell surface, neither major changes in other
phenotypic markers nor on the ability of DCs to stimulate T cell
proliferation and IFN-g production were observed (Figure 4C).
Similarly, exposure of human 1,25D3-DCs to etomoxir, an inhib-
itor that prevents FA transport into the mitochondria and thusMetabolism
sed genes corresponding to proteins included in the oxidative branch of the
1, ATP5A1, and LDHA by qRT-PCR in Ctr- (white bars) or 1,25D3-dMo (black
(AMPK) was performed by qRT-PCR of Ctr- (white bars) or 1,25D3-dMo (black
–3 after addition of 1,25(OH)2D3 and differentiation media. Protein levels of
ern blot; the bar graphs represent the average ratio ± SEM of the percentage
rn blot (n = 3; *p < 0.05; N.D., not detectable).
os and in fully differentiated Ctr- or 1,25D3-DCs. Bar graphs illustrate the fold
compared to controls (n = 4; *p < 0.05, ***p < 0.001, ****p < 0.0001).
(white bar) or 1,25(OH)2D3-modulated iDCs (black bar); mitochondrial mass
25D3-iDCs (n = 3; *p < 0.05).
white bars) or 1,25D3-DCs (black bars) (n = 3–4; ***p < 0.001 as compared to
easured parameters in Ctr- (white bars) or 1,25D3-DCs (black bars).
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AB
Figure 3. 1,25(OH)2D3-Modulated DCs
Depend on Glucose Availability to Maintain
Their Tolerogenic Phenotype
Human Ctr- and 1,25D3-DCswere obtained in vitro
in the presence of (A) 1–10 mM glucose or (B)
0.2%–21% O2. Ctr- (white bars) or 1,25D3-DCs
(black bars). Cells were analyzed by FACS for the
detection of surface expression of different
markers (CD86, CD80, HLA-DR) (n = 4–10; *p <
0.05, **p < 0.01). Values depicted in the bar graphs
represent the levels of the mean fluorescence in-
tensity (MFI) ±SEM from cell-surface markers.
ELISA was used to analyze the release of the cy-
tokines IL-10 and IL-12p70 to the culture super-
natants, and the values were then expressed as
the ratio IL-10/IL-12p70 (n = 4–10, *p < 0.05, **p <
0.01, ***p < 0.001). Proliferation of labeled T cells
was analyzed after 4 days in coculture by means of
eFluor670 cell proliferation dye dilution. The results
were expressed as percentage ±SEM of prolifer-
ation inhibition of CD4+ (left) or CD8+ (right) T cells,
with proliferation in the presence of Ctr-DCs set as
100% (n = 4; *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001); IFN-g levels were measured in
culture supernatants of the DC:T cell cocultures
(n = 4, ***p < 0.001).
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reduces FA oxidation rates (Figure 4A), did not alter the tolero-
genic phenotype and function of 1,25D3-DCs (Figure 4D). Alto-
gether, these results suggest that glycolysis, but not glucose
or FA oxidation, influences the tolerogenic phenotype onset in
1,25D3-DCs.
The PI3K/Akt/mTOR Pathway Is Essential for
1,25(OH)2D3-Modulated DCs to Maintain Their
Tolerogenic Phenotype In Vitro
The findings described above suggest that human 1,25D3-DCs
rely onglucoseavailability andaerobic glycolysis tomaintain their
tolerogenic properties. Signaling through the PI3K/Akt/mTOR
pathway is central to the regulation of glycolytic metabolism (Lo-
casale andCantley, 2011; Shaw andCantley, 2006), and, consis-
tent with this, PI3K and Akt play an essential role in sustained
commitment to glycolysis in activated DCs (Krawczyk et al.,
2010). Because this pathway also controls the expression of C-
MYC, a transcription factor that plays an essential role in facili-
tating glycolysis, and of different proteins involved in glucose up-
take and glycolytic enzymes (Figure 5A), we further investigated
its impact on the induction of human 1,25D3-DCs. PIK3CG, one
of the catalytic subunits of the PI3K complex, was found upregu-
lated at the mRNA level, as evidenced both by microarray
analysis and by qRT-PCR (versus Ctr-DCs) (Figure 5B). In addi-
tion, expression of C-MYC was upregulated in 1,25D3-DCs, as
compared to controls (Figure 5B). Furthermore, although mRNA
expressionofAKTwasdownregulated in1,25D3-DCs (Figure5B),
the levels of p-Akt were maintained constant in 1,25D3-DCs, but
decreased in Ctr-DCs. This resulted in a 6.03 ± 1.82-fold upregu-
lation of activated Akt in treated cells, as compared to controls,
72 hr after exposure of dMo to 1,25(OH)2D3 (Figures 5C and
5D). The functional activation of Akt was confirmed by the
increased phosphorylation of two of its downstream targets,
namely, mTOR and GSK-3b, 48 and 72 hr after exposure of
dMo to 1,25(OH)2D3, respectively (Figures 5C and 5D).
We next explored the role of the PI3K/Akt/mTOR pathway on
the phenotype and function of human 1,25D3-DCs by making
use of different small molecule inhibitors (Figure 6A). Inhibition
of the PI3K/Akt/mTOR pathway by LY294002, a specific PI3K-in-
hibitor, or by rapamycin (RAPA), a natural mTOR inhibitor,
completely normalized the decrease of glucose levels previously
observed in 1,25D3-DC cultures (Figure 6B). Similar data were
obtained when normalizing the glucose levels to the amount of
living cells in the culture (data not shown). This was paralleled
by normalization of the expression of CD86 and HLA-DR in
LY294002-1,25D3-DCs (versus vehicle-1,25D3-DCs), as well as
a trend for increased CD80 expression (Figure 6B). In line with
these findings, LY294002-1,25D3-DCs had decreased IL-10/IL-
12p70 ratios,when compared to vehicle-1,25D3-DCs (Figure 6A),
demonstrating a full phenotype prevention in LY294002-1,25D3-
DCs. Addition of RAPA to the DC cultures induced, to some
extent, similar effects as LY294002 with restored CD86 expres-
sion and decreased IL-10/IL-12p70 ratios, as compared to
respective controls (Figure 6B). Of interest, 1,25D3-DCs were
largely dependent on the PI3K/Akt/mTOR pathway for survival,
as shown by the increased cell death levels in vitro when
1,25D3-DCs were cultured in the presence of either LY294002
or RAPA (versus vehicle-1,25D3-DCs) (Figure S6A).CeDifferentiation of DCs in the presence of AICAR, an AMPK-
activator, produced similar, although less clear, surface marker
expression changes in 1,25D3-DCs. This was paralleled by a
similar restoration of media glucose levels (versus vehicle-
1,25D3-DCs) (Figure 6B). Of note, AICAR-1,25D3-DCs secreted
increased IL-10/IL-12p70 ratios (Figure 6B). Together, these
data clearly indicate that 1,25(OH)2D3 relies on the PI3K/Akt/
mTOR axis to induce and maintain a stable tolerogenic pheno-
type in human-monocyte-derived 1,25D3-DCs.
Finally, we investigated whether other immunomodulatory
compounds (dexamethasone [DEX], ITF2357 [a histone deacety-
lase inhibitor], IL-10, and RAPA) also rely on PI3K/Akt/mTOR to
induce tolerogenicity in human-monocyte-derived DCs. First,
we observed that none of these compounds induced the charac-
teristic decrease in media glucose levels previously observed
in 1,25D3-DC cultures (Figure 6D). Furthermore, none of the
surface marker molecules investigated showed altered expres-
sion when the PI3K/Akt/mTOR pathway was blocked using
LY294002 (Figure 6D) or AICAR (Figure S5B). These findings
suggest a different mechanism of action for 1,25(OH)2D3, as
compared to the other tolerance-inducing agents, in the induc-
tion of tolDCs, with glycolysis and the PI3K/Akt/mTOR pathway
being uniquely required by 1,25(OH)2D3. The other types of
tolDCs do, however, seem to rely on the PI3K pathway for sur-
vival (Figure S6C).
Inhibition of the PI3K/Akt/mTOR Pathway Reverses the
Tolerogenic Function of 1,25(OH)2D3-Modulated DCs
To elucidate the functional impact of the PI3K pathway on the
induction of 1,25D3-DCs, we investigated whether their T cell
activation capacity could be restored by directly interfering
with this pathway using LY294002 or RAPA. As expected,
1,25D3-DCs decreased CD4
+ and CD8+ T cell proliferation
and decreased IFN-g production, as compared to Ctr-DCs.
Addition of LY294002 or RAPA to 1,25D3-DCs prevented the
function of these tolDCs, as shown by a partial restoration of
T cell proliferation when compared to vehicle-1,25D3-DCs;
this was particularly evident in the case of CD4+ T cells (Fig-
ure 7A). In agreement with the surface phenotype expression
of tolDCs obtained in the presence of different tolerogenic
compounds and LY294002, this functional impairment of the
tolDC phenotype was only induced in LY294002-1,25D3-DCs
and not with the other tolerogenic agents (data not shown).
The increased T cell proliferative response was paralleled by
an increased production of IFN-g into the supernatant of the
cocultures (Figure 7B), indicating that the PI3K/Akt/mTOR
pathway is essential for human 1,25D3-DCs to maintain not
only their tolerogenic phenotype, but also their immunoregula-
tory function.
DISCUSSION
Immune cells do not only depend on nutrients for survival, but
oxygen and energy source also determine to a large extent
their fate and functional status. Several environmental and
other clues influence the metabolic switches in these cells (Del-
mastro-Greenwood and Piganelli, 2013). Most of the phenom-
ena accompanying immunological responses involve changesll Reports 10, 711–725, February 10, 2015 ª2015 The Authors 717
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Figure 4. 1,25(OH)2D3-Modulated DCs Depend on Glycolysis, but Not on Glucose or FA Oxidation, to Induce and Maintain Their Tolerogenic
Phenotype
(A) The concentrations of inhibitors used were tested in 1,25D3-DCs (2-DG and DCA) or Ctr-DCs (etomoxir), and cells were further evaluated for glucose and FA
oxidation using radiolabeled metabolites, as well as for the secretion of lactate into de media.
(B) Human Ctr- and 1,25D3-DCs were obtained in vitro in the presence of 5 mM 2-DG or 10 mM glucose. Ctr- (white bars) or 1,25D3-DCs (black bars) were
analyzed by FACS for the detection of surface expression of different markers (CD86, CD80, HLA-DR) (n = 4–10; *p < 0.05, **p < 0.01). Values depicted in the bar
(legend continued on next page)
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Figure 5. The PI3K/Akt/mTOR Axis Is Activated in 1,25(OH)2D3-Modulated DCs
(A) Schematic representation of the PI3K-Akt-mTOR pathway. Indicated genes were identified as differentially expressed upon 1,25(OH)2D3 treatment after
microarray analysis (italic and underlined font, black color), identified after microarray analysis with differential expression confirmed by qRT-PCR (italic font;
green color: upregulated genes; red: downregulated gene), or confirmed to be differentially expressed in 1,25D3-DCs (versus Ctr-DCs) at the protein level (green
font).
(B) Confirmation of differential expression of PIK3CG, AKT1, and C-MYC by qRT-PCR analysis of Ctr- (white bars) or 1,25D3-DCs samples (n = 5–6; *p < 0.05).
(C) Total protein lysates of Ctr- and 1,25D3-DCs samples prepared at days 1–3 after addition of 1,25(OH)2D3 and differentiation media. Protein levels of phos-
phorylated and total Akt/GSK-3b/mTOR (normalized to b-actin) were determined by western blot.
(D) The bar graphs represent the average ratio ± SEM of the percentage induction/inhibition of the analyzed proteins in Ctr- versus 1,25D3-DCs by western blot
(n = 3; *p < 0.05).in gene expression that are thermodynamically demanding,
requiring fast metabolic adaptations (Delmastro-Greenwood
and Piganelli, 2013; Frauwirth and Thompson, 2004; Krauss
et al., 2001). Understanding how metabolic transitions aregraphs represent the levels of the mean fluorescence intensity (MFI) ±SEM from c
10 and IL-12p70 to the culture supernatants, and the values were then express
Proliferation of labeled T cells was analyzed after 4 days in coculture by mean
percentage ± SEM of proliferation inhibition of CD4+ (left) or CD8+ (right) T cells, w
0.01, ***p < 0.001, ****p < 0.0001); IFN-g levels were measured in culture supern
(C and D) Human DCswere obtained after in vitro treatment with 5mmDCA (C) or 2
***p < 0.001, ****p < 0.0001).
Ceinduced and the nature of their role in supporting or directing
phenotypic and functional alterations in immune cells during
immune-mediated processes may open new paths for drug
development (Pearce and Pearce, 2013).ell-surface markers. ELISA was used to analyze the release of the cytokines IL-
ed as the ratio IL-10/IL-12p70 (n = 4–10, *p < 0.05, **p < 0.01, ***p < 0.001).
s of eFluor670 cell proliferation dye dilution. The results were expressed as
ith proliferation in the presence of Ctr-DCs set as 100% (n = 4; *p < 0.05, **p <
atants of the DC:T cell cocultures (n = 4, ***p < 0.001).
0mM etomoxir (D) and analyzed as described in (B) (n = 4, *p < 0.05, **p < 0.01,
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The present findings show an early reprogramming of key
metabolic pathways by 1,25(OH)2D3, initiated at the mRNA level
already at 24 hr after exposure of human dMo to the hormone.
This is in agreement with and builds further on our previous
findings, where we observed major alterations in metabolic
proteins, exclusively in 1,25D3-DCs, and not in DEX-modulated
DCs (Ferreira et al., 2012). These changes are accompanied by
an induced oxidative metabolism in 1,25D3-DCs, as evidenced
by increased intracellular ATP and ROS production, increased
mitochondrial mass and membrane potential, elevated OCR,
and induced glucose oxidation rates. Such a switch to OXPHOS
linked to a tolerogenic profile is in line with earlier observations
indicating that the induction of M2 macrophages in response
to IL-4 involves metabolic reprogramming toward FA oxida-
tion and mitochondrial biogenesis, whereas inhibition of oxida-
tive metabolism attenuates the anti-inflammatory program of
macrophage activation (Vats et al., 2006). In addition, activated
AMPK, which regulates FAO by phosphorylating and inhibiting
ACC and consequently stimulating carnitine palmitoyltransfer-
ase 1 (CPT1a), the rate-limiting enzyme in FAO, is crucial for
Treg development, whereas the Akt/mTOR axis is a negative
regulator of de novo Treg differentiation and population expan-
sion (Michalek et al., 2011; Zeng et al., 2013). Moreover, activa-
tion of AMPK contributes for the generation of murine tolDCs
in the presence of IL-10 (Krawczyk et al., 2010). We have pres-
ently observed a parallel induction of OXPHOS and aerobic
glycolysis by 1,25(OH)2D3, with an essential role for the availabil-
ity of glucose in the environment for tolerance induction in human
dMo. We also propose that persistent metabolism of glucose to
lactate in aerobic conditions is essential for the generation of
human 1,25D3-DCs. This metabolic pathway can provide the
necessary carbons to fuel the energy demand for the massive
cytoskeletal-membrane rearrangements occurring during hu-
man DC maturation in the presence of 1,25(OH)2D3 (Ferreira
et al., 2012; Ferreira et al., 2009). The DC cytoskeletal structures
determine cell shape, function, and fate.
The PI3K/Akt/mTOR pathway was also shown to be central in
inducing and maintaining the tolerogenic properties of 1,25D3-
DCs. This combined metabolic effect of 1,25(OH)2D3 in human
DCs is quite unique in literature. Thus, our findings contrast
with previous reports linking glycolysis and the PI3K/Akt/
mTOR pathway to the induction of a proinflammatory profile in
murine DCs and T cells (Dang et al., 2011; Krawczyk et al.,Figure 6. The PI3K/Akt/mTOR Axis Is Essential for the Induction
Modulated DCs
(A) Simplified representation of the PI3K-Akt-mTOR pathway illustrating target p
(AICAR) used.
(B) HumanCtr- or 1,25D3-DCswere obtained in vitro in the presence of 1.5 mMLY2
FACS to detect their surface expression of different markers (CD86, HLA-DR, CD8
in the bar graph represent average MFI levels ± SEM from surface molecules a
RAPA, or AICAR. ELISA was used to analyze the release of the cytokines IL-10 an
ratio IL-10/IL-12p70 (n = 3–5; **p < 0.01, ***p < 0.001). Glucose content of DC cul
(n = 3–7, *p < 0.05, ***p < 0.001, ****p < 0.0001).
(C) Schematic representation of the DC differentiation/maturation process from
monocytes to iDCs; 2 days in culture during the maturation period, as mentione
compounds is indicated in the figure.
(D) Ctr- and variously treated tolDCs (with DEX, ITF2357, RAPA or IL-10), cultured
surface marker expression, cytokine release to the medium, and media glucose
Ce2010; Michalek et al., 2011; Shi et al., 2011). On the other
hand, recent data indicate that murine T cell proliferation/survival
is largely dependent on OXPHOS, not requiring a switch to aer-
obic glycolysis (Pearce and Pearce, 2013). In addition, FoxP3
gene expression, a classical Treg marker, is controlled by HIF-
1a signaling via mTOR (Clambey et al., 2012), thus demon-
strating the importance of this pathway in the function of Tregs
(Zeng et al., 2013). Finally, effector T cells have increased
OXPHOS in conjunction with glycolysis, which is maintained
even after achieving full activation (Sena et al., 2013; van der
Windt et al., 2012; Wang and Green, 2012).
This particular metabolic profile induced by 1,25(OH)2D3 in
DCs determines their tolerogenic phenotype and function,
as the tolerogenic properties of these cells could only be fully
established when glucose is available and the PI3K/Akt/mTOR
pathway is functional. In addition, the amount of available
glucose, especially at the start of the differentiation process
from human monocytes, is essential for the development of
1,25D3-DCs. Nutrient deprivation itself may interfere with this tol-
erogenic network through decreasing ATP levels. The resulting
increased AMP/ATP ratio is then sensed by AMPK, which, in
turn, phosphorylates TSC2, inhibiting mTOR downstream from
PI3K and Akt (Figure 7C; Dang, 2012). Finally, culturing DCs in
low oxygen concentrations only had a limited impact on the
phenotype of 1,25D3-DCs, whereas no impairment of their tol-
erogenic function was observed. This suggests that the increase
in glucose oxidation and in the expression of OXPHOS-related
genes by 1,25(OH)2D3 is not an underlying cause for the in-
duction and maintenance of the observed tolerogenic DC
phenotype. Because 1,25D3-DCs have been shown to migrate
in vivo and exert their function in sites of inflammation where
oxygenmay be limiting (Ferreira et al., 2014), the fact that hypox-
ia does not change their tolerogenic function is an important
observation.
Most importantly, our data show that PI3K and its downstream
pathway are essential not only for maintenance of the 1,25D3-DC
phenotype, but also for their functional impact on T cells. We
hypothesize that vitamin D receptor (VDR)-bound 1,25(OH)2D3
acts via the PI3K/Akt/mTOR pathway to control the expression
of different cell-surface molecules (Bocelli-Tyndall et al., 2010)
and the balance between the production of immunomodula-
tory and proinflammatory cytokines (Belladonna et al., 2008;
Wang et al., 2011) (Figure 7C). Indeed, preliminary data in DCsand Maintenance of the Tolerogenic Phenotype in 1,25(OH)2D3-
roteins of the small molecule inhibitors (LY294002 and RAPA) and activators
94002, 10 nMRAPA, 0.1mMAICAR, or vehicle. TheDCswere then analyzed by
0) (n = 4–13; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Values depicted
nalyzed in Ctr- or 1,25D3-DCs cultured in the presence of vehicle, LY294002,
d IL-12p70 to the culture medium, and the values were then expressed as the
ture supernatants measured at the end of the differentiation/maturation period
CD14+ monocytes (6 days in culture during the differentiation period from
d in Experimental Procedures). The strategy regarding the use of tolerogenic
in the presence or in the absence of 1.5 mM LY294002, were analyzed for their
content as described in (A) (n = 4–13).
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Figure 7. Inhibition of the PI3K/Akt/mTOR Reverses the Tolerogenic Function of 1,25(OH)2D3-Modulated DCs
Allogeneic total CD3+ T cells were isolated from healthy donors, labeled with the eFluor670 cell proliferation dye, and cocultured in vitro in the presence of Ctr-,
vehicle-1,25D3-, LY294002-1,25D3-, or RAPA-1,25D3-DCs.
(A) Proliferation of labeled T cells was analyzed after 4 days in coculture by means of eFluor670 cell proliferation dye dilution. The results are expressed as
percentage ± SEM of proliferation inhibition of CD4+ (left) or CD8+ (right) T cells, with proliferation in the presence of Ctr-DCs set as 100% (n = 6; **p < 0.01, ****p <
0.0001).
(B) IFN-g levels in culture supernatants of the DC:T cell cocultures (n = 4, **p < 0.01).
(C) Proposed model for the mechanism of action of 1,25(OH)2D3 in human-monocyte-derived DCs. We hypothesize that VDR-bound 1,25(OH)2D3 activates the
PI3K-Akt-mTOR pathway via either forming a complex and phosphorylating the regulatory subunit of PI3K, or by other unknown mechanisms. This releases and
activates the catalytic subunit, which unleashes the PI3K downstream pathway. Among other functions, activation of this pathway promotes the expression of
different key glycolytic enzymes, which induces glycolysis. Control of surface marker expression and cytokine production by 1,25(OH)2D3 might arise from its
impact on the PI3K pathway, which can control essential transcription factors (e.g., GSK-3b and NF-kB nuclear translocation) or from the direct regulation of
transcription factors, keymetabolic bifunctional enzymes, andRNAbinding proteins. In the absence of glucose or glycolysis, an increase in the AMP/ATP ratio will
be sensed by AMPK, which, in turn, phosphorylates TSC2 and blocks activation of the mTOR complex and its downstream processes. We further consider that
the increase in OXPHOS also seen in 1,25D3-DCs is derived from the excess pyruvate generated during induced glycolysis, in addition to the control of metabolic
enzymes from the oxidative branch by 1,25(OH)2D3.generated from VDR/ mice demonstrate that the phenotypic
alterations induced by 1,25(OH)2D3 in these cells are dependent
on the VDR (data not shown). In line with this, treatment of pri-
mary human monocytes with 1,25(OH)2D3 induces the formation
of a signaling complex in which the VDR-bound 1,25(OH)2D3722 Cell Reports 10, 711–725, February 10, 2015 ª2015 The Authorsassociates with p85, the regulatory subunit of the PI3K com-
plex. This association is essential for 1,25(OH)2D3-mediated
expression of the monocyte surface markers CD14 and CD11b
(Hmama et al., 1999). Under our experimental conditions, con-
trol of surface marker expression and cytokine production by
1,25(OH)2D3 might thus arise from its impact on the PI3K
pathway, which can control essential transcription factors.
A similar phenomenon has been previously suggested for
the effects of GSK-3b on NF-kB nuclear translocation in
LPS-stimulated monocytes (Wang et al., 2011). In addition,
PI3K can also activate C-MYC, which plays an essential role in
facilitating increased rates of glucose uptake and glycolysis
(Jones and Thompson, 2009). Although C-MYC is downregu-
lated by 1,25(OH)2D3 in different tumors (Colston and Hansen,
2002; Heikkinen et al., 2011; Rohan and Weigel, 2009; Salehi-
Tabar et al., 2012), the mRNA levels of this transcription factor
are upregulated in human dMo by 1,25(OH)2D3 already at 4 hr
after the start of the treatment (present data). This may
contribute to the observed increased levels of glycolytic en-
zymes, glucose transporters, and glycolysis in 1,25D3-DCs.
Furthermore, control of the expression of key metabolic en-
zymes might represent an additional underlying mechanism by
which 1,25(OH)2D3 exerts its immunomodulatory effects on hu-
man DCs. This is in line with previous research suggesting that
bifunctional enzymes and RNA binding proteins can coordinate
metabolism and gene expression through RNA/enzyme/metab-
olite networks (Pearce et al., 2013) (Figure 7C).
In conclusion, we showed that glucose availability, glucose-
derived carbon usage and a functional PI3K/Akt/mTOR pathway
are essential to maintain the tolerogenic phenotype of 1,25D3-
DCs. By limiting glucose concentrations in the medium and
blocking the PI3K/Akt/mTOR pathway using small pharmaco-
logical inhibitors, we showed that tolDCs induced specifically
by 1,25(OH)2D3, but not by other tolerogenic compounds, are
largely dependent on these features to maintain their tolerogenic
phenotype and function. Although OXPHOS is thought to be
a general process required for the induction of tolerance in
immune cells, our data identify glycolysis and the PI3K-Akt-
mTOR pathway as central regulators of the tolerogenic proper-
ties of 1,25(OH)2D3-generated DCs. Importantly, after the meta-
bolic reprogramming has taken place in 1,25D3-DCs, these cells
will not depend on a normoxic environment or on normoglycemic
conditions to survive and maintain phenotype. This will allow the
re-educated cells to exert their immunomodulatory effects in vivo
in the inhospitable environments where they will home to restore
tolerance. We believe that these metabolic insights in tolero-
genic DC biology are important to support the development of
DC-based immunotherapies and to influence DC longevity and
their resistance to environmental metabolic stress.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are provided in the Supplemental
Information.
In Vitro Generation of Human-Monocyte-Derived DCs
Human DCs were obtained in vitro from freshly isolated monocytes as previ-
ously described (Ferreira et al., 2012), in accordancewith the ethics committee
of the KU Leuven (Figure S1). For inducing DC differentiation, isolated mono-
cytes were cultured in differentiation media with 1,000 U/ml recombinant
human IL-4 (Gentaur) and 800 U/ml recombinant human GM-CSF (Gentaur).
Medium and cytokines were refreshed on day 3. On day 6, media was replen-
ished and maturation was induced in the iDC cultures by 100 ng/ml LPS
(Sigma), 1,000 U/ml recombinant human IFN-g (Roche), and 800 U/ml GM-
CSF (Gentaur).CeChemical Compound Treatment
1,25(OH)2D3 (10
8 M) (Sigma), dexamethasone (DEX, 106 M) (Panpharma),
Givinostat (ITF2357, 100 nM) (Selleckchem/Divbio Science), and RAPA
(10 ng/ml) (Roche) were added at the beginning of the culture at the indicated
final concentrations and refreshed at day 3. Recombinant human IL-10
(40 ng/ml) (PeproTech) was added on day 6 of culture. DCA (5 mM) (Sigma),
etomoxir (20 mM) (Calbiochem-EMD Millipore), LY294002 (1.5 mM) (Calbio-
chem-EMD Millipore), and AICAR (0.1 mM) (Calbiochem-EMD Millipore)
were added every day to the DC cultures, 30min before addition of tolerogenic
compound or maturation stimulus. Similar dilutions of ethanol, DMSO, or PBS
were used as vehicle controls.
Flow Cytometry Analysis of Human DC Surface Markers
Ctr- and 1,25D3-DCs were analyzed for their surface marker expression by
fluorescence-activated cell sorting (FACS). All staining procedures were per-
formed in PBS containing 2mMEDTA and 0.1%BSA. Cells were preincubated
with anti-CD16/CD32 to minimize nonspecific binding. Thereafter, 2.5 3 105
cells were labeled with the following conjugated antibodies: CD1a (from Bio-
Legend), CD14 and HLA-DR (from Affymetrix/eBioscience), CD80 and CD86
(from BD Biosciences), and matching isotype controls. Signal height and
widths were used to exclude doublets. Dead cells were excluded by using
the Fixable Live/Dead Yellow stain according to the manufacturer’s specifica-
tions (Invitrogen). Data acquisition was performed on a Gallios flow cytometer
(BeckmanCoulter Genomics), and the Kaluza software (BeckmanCoulter) was
used for data analysis.
Isolation of Allogeneic Human T Cells, In Vitro Lymphocyte
Proliferation, and FACS Analysis
PurifiedCD3+ T cells were prepared fromperipheral bloodmononuclear cells of
healthy donors using the Pan T cell II kit (Miltenyi Biotec), according to theman-
ufacturer’s instructions. Purity was routinely 90%–95%, as assessed by FACS.
Purified allogeneic CD3+ T cells were labeled with the eFluor670 Proliferation
Dye (Affymetrix/eBioscience) and cocultured with (extensively washed) DCs at
a 1:10–50DC:T cell ratio. Cellswere cultured for 4 days before antibody staining
and FACS analysis. T cell proliferation was assessed by simultaneous staining
for CD4 and CD8 (from Affymetrix/eBioscience). Cells were gated based on
the forward and side scatter (lymphocyte gate) and signal height and widths
(doublet exclusion). Further analysis was performed as described above.
Statistical Analysis
Data were tested for statistical significance using the paired t test, one sample
t test, or one-way ANOVA with subsequent Tukey post-test for multiple com-
parisons, using the GraphPad Prism software. For all tests, data were consid-
ered significantly different at p < 0.05.
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